RECRUITING

Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and hemorrhagic post-operative complications. The investigators further hypothesize that there is histologic pathology correlates to pre-operative TEG abnormalities, and that it identifies patients with virulent tumor biology.

Official Title

Use of Viscoelastic Assays Beyond Coagulation: Pre- and Post-operative TEG

Quick Facts

Study Start:2022-06-01
Study Completion:2028-07-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05517811

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 99 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * new diagnosis by the providing physician of hepatopancreaticobiliary, esophageal, colorectal or lung adenocarcinoma will be eligible for enrollment in the study
  2. * 18 Years and older
  1. * Under 18 years old
  2. * prisoners
  3. * those unable to provide informed consent
  4. * pregnant women
  5. * and those undergoing emergent or urgent operative intervention at the time of diagnosis

Contacts and Locations

Study Contact

Tracey MacDermott, BA BS CCRC
CONTACT
303-724-2757
tracey.macdermott@cuanschutz.edu
Ivan Rodriguez, MD
CONTACT
ivan.rodriguez@cuanschutz.edu

Principal Investigator

Marco Del Chiaro, MD
PRINCIPAL_INVESTIGATOR
University of Colorado, Denver

Study Locations (Sites)

University of Colorado Denver
Aurora, Colorado, 80045
United States

Collaborators and Investigators

Sponsor: University of Colorado, Denver

  • Marco Del Chiaro, MD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-01
Study Completion Date2028-07-31

Study Record Updates

Study Start Date2022-06-01
Study Completion Date2028-07-31

Terms related to this study

Additional Relevant MeSH Terms

  • Liver Cancer
  • Esophageal Cancer
  • Colorectal Cancer
  • Lung Adenocarcinoma
  • Control
  • Pancreas Cancer
  • Biliary Cancer